anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is a double-blind, placebo-controlled trial in which trauma victims are randomized to receive a single intranasal administration of either Oxytocin (40IU) or placebo within the first six hours following trauma exposure. To provide a pre-treatment baseline, participants will receive a medical and psychological evaluation prior to treatment. After two weeks the research assistant or study psychiatrist will perform behavioral ratings and complete history details pertaining to PTSD risk factors. Participants will be assessed again by the study psychiatrist or research assistants at 1, 3, 6 and 13 months. Eligible subjects will include men and women over the age of 18, who have been exposed to an event meeting the DSM-IV "A.1" criterion for trauma exposure, and who provide written, informed consent to participate in the study. In order to recruit persons who are more likely to be at risk for the development of PTSD, we will only randomize persons expressing marked anxiety, emotional distress or dissociation, as assessed by the Visual Analog Scales. Potential participants will be recruited from trauma victims arriving at the Chaim Sheba Medical Center Emergency Room.
Patients undergo SRS or SRT within 15 days of randomization followed by surgery within 15 days of radiation completion. Patients may undergo additional SRS or SRT if disease returns after treatment.
First package information indicating a size or weight of each of packages and first delivery route information indicating first delivery routes are acquired from a memory, where each of the first delivery routes starts from a delivery start point, passes through destinations to which the packages are to be delivered, and ends at the delivery start point. An evaluation value for each of the first delivery routes is calculated based on the first package information and the first delivery route information. An optimum first delivery route is determined, based on the calculated evaluation values, from among the first delivery routes. Information indicating the determined first delivery route is output to an information terminal. The determined first delivery route is displayed on a display of the information terminal. A delivery person delivers the packages to the destinations along the determined first delivery route.
FIELD: medicine. SUBSTANCE: method involves applying plaster immobilization. Neaton (phosphocreatine) is administered as 5 intramuscular injections course into traumatized muscle ends at a dose of 1000 mg/day. Intravenous injections are administered each second day at a dose of 3000 mg/day as 5 injections long course. Plaster immobilization is interrupted in 6 days. Active movements in adjacent joints are carried out during 4 days. The movements are done within the pain feeling limits three times a day during 10-15 min. Movements are to be slow. EFFECT: enhanced effectiveness of treatment; complete recovery of injured region.
BACKGROUND: The aim of this study was to quantify serum levels of elafin, a serine protease inhibitor, and to assess its effects on histopathological and biochemical parameters in hepatic ischemia-reperfusion injury.
METHODS: Forty female Wistar albino rats were divided into five groups: Group 1 served as the control group. Liver ischemia was induced for 30 minutes in the other four groups. An additional 1-hour, 2-hour, and 3-hour reperfusion was induced in Groups 3, 4, and 5, respectively. At the end of the experiment, intracardiac blood samples were obtained for biochemical examination, and tissue samples from the liver were taken for histopathological examination. Levels of elafin, ischemia-modified albumin (IMA), total antioxi-dant status (TAS), and total oxidant status (TOS) were also examined.
RESULTS: Serum elafin levels decreased beginning from Group 2, with the lowest level reached in Group 5 (p<0.01). The IMA level was the lowest in the control group and the highest in Group 5 (p<0.01). TOS, aspartate aminotransferase (AST), and alanine amino-transferase (ALT) levels were lowest in the control group and highest in Group 5 (p<0.01). Group 5 had the highest IMA/albumin ratio, although no significant differences were found between these four groups. The lowest TAS level was found in the control group, but a stable and significant increase was not detected in the other groups. No significant differences were found between the groups in terms of alkaline phosphatase (ALP) and albumin levels. A negative correlation was observed between serum elafin levels and AST, ALT, and TOS levels (p<0.01). The number of Grade 1 histopathological results was found to be higher in the groups with reperfusion (Groups 3, 4, 5). In histopathological subgroup analysis, while the elafin level was lower in Grade 1 group, AST, ALT, and TOS levels were higher (p<0.01). Additionally, the IMA/albumin ratio was found to be higher in the Grade 1 group (p=0.02).
CONCLUSION: In hepatic ischemia-reperfusion injury, elafin levels decreased as the reperfusion time increased. As the reperfusion time increased, both hepatocyte damage and oxidant capacity increased, with a negative correlation observed between these findings and elafin levels. Therefore, elafin may play a protective role in hepatic ischemia-reperfusion injury and could assist clinicians in assessing liver injury.
Various methods and compositions of treating 4-hydroxyphenylpyruvate dioxygenase-like (HPDL)-r elated diseases or disorders are presented herein. Also presented herein are methods of increasing CoQlO biosynthesis, and methods of determining whether a subject will benefit from a CoQlO or CoQlO alternative treatment. Also presented herein are pharmaceutical compositions and dosage forms comprising 4-hydroxymandelic acid (4-HMA), and/or its metabolites. Further presented herein are compounds that inhibit 4-hydroxyphenylpyruvate dioxygenase-like (HPDL). Further presented herein are methods of identifying and/or assessing modulators of HPDL. Yet further presented herein are example methods and systems for isotopic labelling in cells by metabolizing cells in the presence of gaseous isotopic tracer.
In the sham (Sham Reiki) group, sham practitioners (not involved in the study) who have no experience in energy work will prepare screens and headphones for the patients as in the intervention group. Then, they will place their hands gently on or above the patient's head and eyes, upper body from the neck to the pelvic region, arms and legs (standard reiki hand positions) for 30 minutes every other day for 2 days in a row or 2 times (Day 1 and Day 3) like the practitioner in the intervention group. Patient data will be recorded on forms before and after placebo administration as in the intervention group.
Every patient of the Mulhouse Hospital with a type 1 diabetes who joins the study will be followed for 10 months. They will fill in the DIAPASON questionnaire and the quality of life WHO-5 questionnaire on the day of enrollment and 10 months after enrollment, at the end of the study. Young patients followed for a type 1 diabetes at the Mulhouse Hospital usually come every two months to see the pediatric endocrinologist, so the data collected for a regular visit will also be collected for the study every two months between the enrollment and the end of study participation.
Patients receive tremelimumab IV over 60 minutes and durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for up to 4 cycles for tremelimumab and up to 13 cycles for durvalumab in the absence of disease progression or unacceptable toxicity.
Drug abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. The abuse potential of daridorexant was evaluated in preclinical models, recreational sedative drug users, and insomnia subjects.

In a human abuse potential study conducted in 63 recreational sedative drug users, the effect of single-dose administration of QUVIVIQ [50 mg, 100 mg (two times the maximum recommended dose), and 150 mg (three times the maximum recommended dose)], zolpidem (30 mg), suvorexant (150 mg), and placebo on subjective rating of "drug liking" was evaluated. At the dose of 50 mg, QUVIVIQ showed significantly lower "drug liking" ratings than zolpidem (30 mg) and suvorexant (150 mg), but significantly higher than placebo. At doses of 100 mg (two times the maximum recommended dose) and 150 mg (three times the maximum recommended dose), QUVIVIQ showed similar "drug liking" ratings to zolpidem (30 mg) and suvorexant (150 mg).

In placebo-controlled Phase 3 clinical studies in which 1232 subjects with insomnia were treated with QUVIVIQ for up to 12 months, there were no reports indicative of abuse liability. Because individuals with a history of abuse of or addiction to alcohol or other drugs may be at increased risk for abuse of or addiction to QUVIVIQ, follow such patients carefully.
This group will receive standard antiseptic preparation with chlorhexidine in alcohol applied in a circular area (2-3 cm radius) around the puncture site for 2 minutes. Following antiseptic cleaning and the physician will immediately perform the arterial blood sampling procedure with heparinized 3mL arterial blood gas syringe with a 22G x 1" needle.
This invention describes an cellular and subcellular “social network” at a biomolecular level that provides systems and methods for life extension, disease prevention and cellular rejuvenation through the transfer or exchange of biochemical, electrophysiological and sub-cellular biomolecular constructs and/or their assemblies, either in their totality or in part as carriers of material and/or information through interactions and continuous intercourses between neighboring cells. First responder cells are engineered or primed to support such conveyances including, but not limited to: organelles, macromolecules, lipids, ions, etc. from cells able to dispose of said biomaterials, etc. to cells requiring or standing to benefit therefrom. Among other advantages, these systems and methods provide increased capacity for managing intact mitochondrial (switching) mechanisms for the restoration or improved functionality of compromised cells. As cells or cellular clusters signal or are recognized by neighboring cells, cellular assemblage(s) or biomass, they receive mitochondria that are tagged, selected or engineered for cyto-enhancement. First responder cells may be cells native to the organism in situ; cells native to the organism, but removed and cultured or modified in growth media, optionally synthetically induced to express improved functionality, and returned per ipsis or combined with restorative media to aid healing. Additional immunologically compatible cells cultured from sources other than those native to the organism may be provided as an aid to healing. This process may be activated by using chemical, physical or harmonic activators or a combination thereof.
The invention relates to a preparation for facilitating wound healing. A cell culture medium is included and formed by culturing transferred endothelial presoma cells, and the transferred endothelial pregenitor cells are formed by transferring tiny ribonucleic acid let-7 g to one endothelial pregenitor cell. The preparation method of the preparation for facilitating wound healing comprises a separation step, a transferring step and a culture step. According to the separation step, mononuclear cells are separated out from human whole blood, and the mononuclear cells are inoculated on a human-fibronectin-coated plate to obtain the endothelial pregenitor cells. According to the transferring step, the tiny ribonucleic acid let-7 g is transferred to the endothelial pregenitor cells to obtain the transferred endothelial pregenitor cells. According to the culture step, the transferred endothelial pregenitor cells are cultured for a preset period of time to obtain the preparation for facilitating wound healing.
PROBLEM TO BE SOLVED: To obtain a cosmetic excellent in smoothness, spreadability, uniformity, adhesivity and transparency by using a specific metal oxide. SOLUTION: This cosmetic contains a collapsible hollow porous metal oxide. The metal oxide is obtained e.g. by mixing the dispersion of a collapsible core nuclear substance with a metal oxide capable of being adhered and flocculated to the substance, removing the dispersing medium of the dispersion to adhere and flocculate the metal oxide to the core nuclear substance, and subsequently collapsing the core nuclear substance. The metal compound is preferably the fine particles or ultrafine particles of the oxide of a metal such as Ti, Al, Zr, Si or Ni, the alkoxide of the metal, the acetylacetate of the metal, etc. The core nuclear substance is preferably a substance capable of being collapsed with heat, an acid or a base. The collapsible hollow porous metal oxide preferably carries a functional effective substance and/or a coloring agent, and has a particle diameter of 0.1-100μm.
The present invention is concerned with means and methods for diagnosing or treating HPV associated neoplasia or tumors. Specifically, it relates to a peptide comprising an amino acid sequence motif as shown in SEQ ID No: 1. Moreover, contemplated by the present invention are fusion polypeptides, polynucleotides, vectors and host cells based on said peptide. Furthermore, the peptides, fusion polypeptides, polynucleotides, and vectors are suitable as pharmaceutical compositions for treating HPV associated neoplasia or tumors. The peptides and fusion polypeptides are also suitable as diagnostic compositions for diagnosing HPV associated neoplasia or tumors. The present invention also refers to a method of identifying a compound capable of binding to the HPV E6 protein. Finally, a kit is provided for carrying out the aforementioned diagnosis or compound identification.
FIELD: cosmetology. SUBSTANCE: composition includes washing base in cosmetically acceptable medium containing at least one anionogenic surface-active substance of alkylethersulfate type and conditioning system containing at least one insoluble nonamino silicon and at least one cation polymer selected from homopolymers of diallyldimethylammonia. The method of washing and conditioning keratin substances such as hair is carried out by applying required quantity of composition on wet hair and washing it out by water. The composition gives hair better easy combing, volume, softness and shine. EFFECT: improved washing ability. 11 cl, 3 tbl, 3 ex
Twenty patients in the FFP group receive 4 units of FFP (Octaplas). Additional fibrinogen (Riastab) is administered (if needed) to increase the baseline FIBTEM-MCF (at 5 min) to the target of 15 mm. The fibrinogen content of the FFP will be taken into consideration (2.1 g in 4 units of FFP).
Meta-analyses are a central part of systematic reviews. The term meta-analysis describes the statistical methods to summarize the results of the available scientific studies providing the highest possible evidence. In medicine, meta-analyses aim to guide clinical decisions. This article provides an overview of the necessary work steps.The classical meta-analysis summarizes the results of randomized controlled trials that compare an intervention against a control intervention. This is illustrated by means of an example from a Cochrane Review on videolaryngoscopy in comparison to direct laryngoscopy. Crucial methodological aspects such as the weighting of individual studies when pooling their results as well as the evaluation of study heterogeneity and potential publication bias are explained.The second part of the article focusses on two extensions of meta-analyses: the individual patient data meta-analysis and the network meta-analysis. The individual patient data meta-analysis makes use of the information that is available from the patient-level data of the included studies. As an example, the work accomplished by an international collaboration on the efficacy of acupuncture in chronic pain is presented. A network meta-analysis enables the comparison of more than two interventions by making use not only of the available direct but also of the respective indirect evidence. This is illustrated by means of a Cochrane Review on drugs for the prophylaxis of postoperative nausea and vomiting.
For the first 2 weeks of the study, participants received aliskiren 150 mg once a day and were then forced titrated to aliskiren 300 mg once a day for 52 weeks. Participants also received a placebo capsule to match ramipril once a day for the study duration.
BACKGROUND: RNA binding proteins (RBPs) play a role in sorting non-coding RNAs (ncRNAs) into exosomes. These ncRNAs, carried by exosomes, are involved in regulating various aspects of tumor progression, including metastasis, angiogenesis, control of the tumor microenvironment, and drug resistance. Recent studies have emphasized the importance of the RBP-ncRNA-exosome mechanism in tumor regulation.
AIM OF REVIEW: This comprehensive review aims to explore the RBP-ncRNA-exosome mechanism and its influence on tumor development. By understanding this intricate mechanism provides novel insights into tumor regulation and may lead to innovative treatment strategies in the future.
KEY SCIENTIFIC CONCEPTS OF REVIEW: The review discusses the formation of exosomes and the complex relationships among RBPs, ncRNAs, and exosomes. The RBP-ncRNA-exosome mechanism is shown to affect various aspects of tumor biology, including metastasis, multidrug resistance, angiogenesis, the immunosuppressive microenvironment, and tumor progression. Tumor development relies on the transmission of information between cells, with RBPs selectively mediating sorting of ncRNAs into exosomes through various mechanisms, which in turn carry ncRNAs to regulate RBPs. The review also provides an overview of potential therapeutic strategies, such as targeted drug discovery and genetic engineering for modifying therapeutic exosomes, which hold great promise for improving cancer treatment.
After screening, participants will be randomized to ASP3772 or PCV13 on Day 1. A single dose of ASP3772 will be administered on Day 1 as an injection into the right or left thigh muscle at one of three dose levels. The participants randomized to PCV13 will receive a single intramuscular injection of the approved dose of PCV13 into the right or left thigh muscle. All participants will remain at the study site for approximately 30 to 60 minutes following vaccination in order for study site personnel to evaluate any immediate reactions, if needed. The participant's parent/legal guardian will observe for reactions, including daily body temperature measurements and tolerability assessments, from Day 2 through Day 7 and record observed events in the electronic diary device.

All participants will have study visits on Day 7 (+ 1 day) and Day 30 (± 5 days) post-vaccination. The Day 7 visit may be conducted on site or by telephone call.The end-of-study visit will occur on Day 180 (± 14 days), which will be a safety follow-up by telephone call.
Teratogenic Effects: Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. Hydrocodone bitartrate and acetaminophen tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. 

Nonteratogenic Effects: Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose. There is no consensus on the best method of managing withdrawal.
BACKGROUND: Breast reduction surgery has witnessed significant advancements in recent years; however, it continues to pose challenges for both surgeons and patients when dealing with cases involving excessive breast volume and severe breast ptosis. This study aimed to assess the aesthetic outcomes and the impact on the quality of life, as measured by the BREAST-Q questionnaire, in patients with gigantomastia and severe breast ptosis who underwent reduction mammaplasty using the superomedial-based pedicle technique.
METHODS: We present a retrospective series comprising 84 patients who underwent reduction mammoplasty utilizing the superomedial pedicle technique. The surgical resections exceeded 1 kg per breast, with a mean resection weight of 1506.58 g (right breast) and 1500.32 g (left breast). The preoperative mean suprasternal notch to nipple distance measured 40.50 cm (right breast) and 40.38 cm (left breast). Postoperatively, the patients were followed up for a minimum of 6 months. Both preoperative and postoperative BREAST-Q surveys were administered to the participants, and scores were analyzed using descriptive statistics.
RESULTS: Complications were observed in 3 patients (3.57%), characterized by partial loss of the areola, which resolved spontaneously over time. Additionally, 2 cases of hematoma and 2 instances of minor delayed wound healing were reported. All patients expressed satisfaction with their aesthetic outcomes, as they achieved a natural breast shape and minimal scarring, along with symptomatic relief.
CONCLUSIONS: The superomedial pedicle reduction mammaplasty technique has demonstrated its ability to produce satisfactory aesthetic outcomes and long-term benefits in patients with excessively large breasts. Careful patient selection and postoperative management are vital for achieving optimal results. Further investigations involving larger sample sizes and longer follow-up periods are warranted to validate our findings.
LEVEL OF EVIDENCE: IV.
The subject matter disclosed herein includes a computerized method that supports the process of data collection for analysis and rationalization of instrument trays within a healthcare environment. The method, performed using a processor, includes for receiving instrument usage information related to instrument trays for use in the healthcare environment. Information related to preference card instrumentation, equipment, and disposable articles is stored within a database. A tray configuration is provided for a determined procedure. Instrument usage information is received, where the instrument suage information is related to instrument trays after use in the healthcare environment. It is determined, based on the received instrument usage after use in the healthcare environment, whether articles placed within an instrument tray are being used at a frequency below a predetermined threshold. Preference card information and tray configuration are updated for the determined procedure based on the determination.
<P>PROBLEM TO BE SOLVED: To provide a rapidly dispersing dosage form, known as a "flash dose".  <P>SOLUTION: The dosage forms release their active ingredients in a term less than about 90 sec. The dosage forms exhibit a three-dimensional shape that is retained for an adequate storage term but is readily dispersed in the presence of excess moisture. The dosage forms contain a massive substance and a binder, preferably, which massive substance is selected from spray-dried lactose, fructose, sucrose, dextrose, sorbitol, mannitol, xylitol and microcrystalline cellulose and which binder is preferably selected from the group consisting of arabinogalactan, polyvinylpyrrolidone, sorbitol, mannitol and xylitol. Also provided are methods of administration of a medicament and a method for producing rapidly dispersing dosage forms.  <P>COPYRIGHT: (C)2009,JPO&INPIT